Recent integrated analysis of three phase-I/II studies (STARTRK-2, STARTRK-1, and ALKA-372-001) showed deep and durable systemic response in patients with ROS1-rearranged NSCLC treated with entrectinib regardless of CNS metastases [13]. Here, ROS1 is linked to non-small cell lung carcinoma.